For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope as more treatment options ...

Morningstar brands and products Company Portfolio ...

Population model successfully developed to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad range of ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.

Researchers are praising the results of two studies that used immunotherapy to fight one of the most difficult-to-treat types of brain cancer, glioblastoma. The studies used CAR-T therapy, which uses ...

Media: Jeffrey Krasner Slowey McManus Communications jkrasner@sloweymcmanus.com +1 (617) 840-9806 Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to ...

As part of a $93 million grant package, the Cancer Prevention and Research Institute of Texas, known for funding ...

Society for Immunotherapy of Cancer (SITC) 2023 poster. 3 Paston, et al (2024). A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced ...